Drug Profile
Insulins - Halozyme
Alternative Names: Analog insulin-PH20; Aspart-PH20; Hyaluronidase-insulin; Insulin-hyaluronidase; Insulin-PH20; Lispro-PH20; Recombinant human hyaluronidase-insulin; rHuPH20/insulin; Ultrafast InsulinLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Halozyme Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Hyaluronidase stimulants; Ornithine decarboxylase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 07 Aug 2015 Phase-II development for Type 1 diabetes mellitus and Type 2 diabetes mellitus is ongoing in USA
- 31 Mar 2015 Insulins - Halozyme is available for licensing as of 31 Mar 2015. http://www.halozyme.com
- 13 Jun 2012 Efficacy and adverse event data from a phase II trial in patients with type 2 diabetes presented at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA-2012)